DNA repair as a determinant of tumour chemosensitivity

Shinya Oda, Isao Kuraoka, Yoshihiko Maehara

Research output: Contribution to journalReview article

3 Citations (Scopus)

Abstract

Differently from target-based anticancer drugs, molecular mechanisms of actions are not well-known in many of the classical antineoplastic agents. With the exception of vinca alkaloids and taxanes, all of the classical antineoplastic agents work on DNA metabolism in cells and can therefore be categorised as 'DNA metabolism inhibitor'. Cellular sensitivity against these drugs largely depends on various activities in DNA metabolism, particularly in DNA repair. However, DNA repair as a determinant of drug sensitivity had long received little attention. DNA mismatch repair (MMR) is now regarded as an important determinant to alter cellular sensitivities against various drugs including fluoropyrimidines, platinum compounds and topoisomerase inhibitors. However, molecular mechanisms of this connection are still unknown. In particular, the relationship between MMR and 5-fluorouraci (l 5-FU) sensitivity is now being approached by examining the tumour MMR status and clinical outcomes in colorectal cancer patients treated with 5-FU-based adjuvant chemotherapies. However, reported results lack consistency, possibly due to the methodological problems in assays used to determine the MMR status. On the other hand, nucleotide excision repair (NER) is also regarded as an important determinant of cisplatin (CDDP) sensitivity. Expression of ERCC 1, a component of this complex multi-protein system, has been reported to be a determinant of prognosis in CDDP-treated non-small-cell lung cancer patients. In order to establish the significance of DNA repair as a determinant of tumour chemosensitivity, further basic studies, particularly ones approached from biochemical viewpoints, are required. Clinical studies supported by accurate assay techniques are also needed.

Original languageEnglish
Pages (from-to)347-357
Number of pages11
JournalGan to kagaku ryoho. Cancer & chemotherapy
Volume34
Issue number3
Publication statusPublished - Jan 1 2007

Fingerprint

DNA Mismatch Repair
DNA Repair
Fluorouracil
Pharmaceutical Preparations
Antineoplastic Agents
DNA
Neoplasms
Topoisomerase Inhibitors
Vinca Alkaloids
Platinum Compounds
Taxoids
Adjuvant Chemotherapy
Non-Small Cell Lung Carcinoma
Cisplatin
Colorectal Neoplasms
Proteins

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Cite this

Oda, S., Kuraoka, I., & Maehara, Y. (2007). DNA repair as a determinant of tumour chemosensitivity. Gan to kagaku ryoho. Cancer & chemotherapy, 34(3), 347-357.

DNA repair as a determinant of tumour chemosensitivity. / Oda, Shinya; Kuraoka, Isao; Maehara, Yoshihiko.

In: Gan to kagaku ryoho. Cancer & chemotherapy, Vol. 34, No. 3, 01.01.2007, p. 347-357.

Research output: Contribution to journalReview article

Oda, S, Kuraoka, I & Maehara, Y 2007, 'DNA repair as a determinant of tumour chemosensitivity', Gan to kagaku ryoho. Cancer & chemotherapy, vol. 34, no. 3, pp. 347-357.
Oda, Shinya ; Kuraoka, Isao ; Maehara, Yoshihiko. / DNA repair as a determinant of tumour chemosensitivity. In: Gan to kagaku ryoho. Cancer & chemotherapy. 2007 ; Vol. 34, No. 3. pp. 347-357.
@article{df4d6e5e59d84dc6b576ce58f2ba2519,
title = "DNA repair as a determinant of tumour chemosensitivity",
abstract = "Differently from target-based anticancer drugs, molecular mechanisms of actions are not well-known in many of the classical antineoplastic agents. With the exception of vinca alkaloids and taxanes, all of the classical antineoplastic agents work on DNA metabolism in cells and can therefore be categorised as 'DNA metabolism inhibitor'. Cellular sensitivity against these drugs largely depends on various activities in DNA metabolism, particularly in DNA repair. However, DNA repair as a determinant of drug sensitivity had long received little attention. DNA mismatch repair (MMR) is now regarded as an important determinant to alter cellular sensitivities against various drugs including fluoropyrimidines, platinum compounds and topoisomerase inhibitors. However, molecular mechanisms of this connection are still unknown. In particular, the relationship between MMR and 5-fluorouraci (l 5-FU) sensitivity is now being approached by examining the tumour MMR status and clinical outcomes in colorectal cancer patients treated with 5-FU-based adjuvant chemotherapies. However, reported results lack consistency, possibly due to the methodological problems in assays used to determine the MMR status. On the other hand, nucleotide excision repair (NER) is also regarded as an important determinant of cisplatin (CDDP) sensitivity. Expression of ERCC 1, a component of this complex multi-protein system, has been reported to be a determinant of prognosis in CDDP-treated non-small-cell lung cancer patients. In order to establish the significance of DNA repair as a determinant of tumour chemosensitivity, further basic studies, particularly ones approached from biochemical viewpoints, are required. Clinical studies supported by accurate assay techniques are also needed.",
author = "Shinya Oda and Isao Kuraoka and Yoshihiko Maehara",
year = "2007",
month = "1",
day = "1",
language = "English",
volume = "34",
pages = "347--357",
journal = "Japanese Journal of Cancer and Chemotherapy",
issn = "0385-0684",
publisher = "Japanese Journal of Cancer and Chemotherapy Publishers Inc.",
number = "3",

}

TY - JOUR

T1 - DNA repair as a determinant of tumour chemosensitivity

AU - Oda, Shinya

AU - Kuraoka, Isao

AU - Maehara, Yoshihiko

PY - 2007/1/1

Y1 - 2007/1/1

N2 - Differently from target-based anticancer drugs, molecular mechanisms of actions are not well-known in many of the classical antineoplastic agents. With the exception of vinca alkaloids and taxanes, all of the classical antineoplastic agents work on DNA metabolism in cells and can therefore be categorised as 'DNA metabolism inhibitor'. Cellular sensitivity against these drugs largely depends on various activities in DNA metabolism, particularly in DNA repair. However, DNA repair as a determinant of drug sensitivity had long received little attention. DNA mismatch repair (MMR) is now regarded as an important determinant to alter cellular sensitivities against various drugs including fluoropyrimidines, platinum compounds and topoisomerase inhibitors. However, molecular mechanisms of this connection are still unknown. In particular, the relationship between MMR and 5-fluorouraci (l 5-FU) sensitivity is now being approached by examining the tumour MMR status and clinical outcomes in colorectal cancer patients treated with 5-FU-based adjuvant chemotherapies. However, reported results lack consistency, possibly due to the methodological problems in assays used to determine the MMR status. On the other hand, nucleotide excision repair (NER) is also regarded as an important determinant of cisplatin (CDDP) sensitivity. Expression of ERCC 1, a component of this complex multi-protein system, has been reported to be a determinant of prognosis in CDDP-treated non-small-cell lung cancer patients. In order to establish the significance of DNA repair as a determinant of tumour chemosensitivity, further basic studies, particularly ones approached from biochemical viewpoints, are required. Clinical studies supported by accurate assay techniques are also needed.

AB - Differently from target-based anticancer drugs, molecular mechanisms of actions are not well-known in many of the classical antineoplastic agents. With the exception of vinca alkaloids and taxanes, all of the classical antineoplastic agents work on DNA metabolism in cells and can therefore be categorised as 'DNA metabolism inhibitor'. Cellular sensitivity against these drugs largely depends on various activities in DNA metabolism, particularly in DNA repair. However, DNA repair as a determinant of drug sensitivity had long received little attention. DNA mismatch repair (MMR) is now regarded as an important determinant to alter cellular sensitivities against various drugs including fluoropyrimidines, platinum compounds and topoisomerase inhibitors. However, molecular mechanisms of this connection are still unknown. In particular, the relationship between MMR and 5-fluorouraci (l 5-FU) sensitivity is now being approached by examining the tumour MMR status and clinical outcomes in colorectal cancer patients treated with 5-FU-based adjuvant chemotherapies. However, reported results lack consistency, possibly due to the methodological problems in assays used to determine the MMR status. On the other hand, nucleotide excision repair (NER) is also regarded as an important determinant of cisplatin (CDDP) sensitivity. Expression of ERCC 1, a component of this complex multi-protein system, has been reported to be a determinant of prognosis in CDDP-treated non-small-cell lung cancer patients. In order to establish the significance of DNA repair as a determinant of tumour chemosensitivity, further basic studies, particularly ones approached from biochemical viewpoints, are required. Clinical studies supported by accurate assay techniques are also needed.

UR - http://www.scopus.com/inward/record.url?scp=34047179506&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34047179506&partnerID=8YFLogxK

M3 - Review article

C2 - 17353624

AN - SCOPUS:34047179506

VL - 34

SP - 347

EP - 357

JO - Japanese Journal of Cancer and Chemotherapy

JF - Japanese Journal of Cancer and Chemotherapy

SN - 0385-0684

IS - 3

ER -